News | July 26, 2025
RPG Life Sciences Q1 FY2026 PAT slips to Rs. 26.29 Cr
RPG Life Sciences has reported total income of Rs. 174.15 crores during the period ended June 30, 2025
RPG Life Sciences has reported total income of Rs. 174.15 crores during the period ended June 30, 2025
The company received one observation in the Form-483
Both these products will be manufactured at Lupin’s Injectable facility at Nagpur, India
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
The coating is designed for heat-sealable applications, offering oil and grease resistance on kraft paper and suitable blister coatings for paper and paperboard
She was Group Chief Marketing Officer at CKA Birla Group in her last role
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
FDA requests Sarepta Therapeutics to suspend distribution of Elevidys and places clinical trials on hold for multiple gene therapy products following 3 deaths
European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
Subscribe To Our Newsletter & Stay Updated
